Editas Medicine (EDIT)CEO sold ~$15K

~$15K

Approx. value · 5,592 sh @ $2.60

275K

Holds after · shares reported

Traded

Sep 3, 2025

Filed

Sep 4, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 31, 2025InsiderOfficer sold ~$13K of EDIT shares in the open market
2. Aug 7, 2025InsiderCFO sold ~$1.8K of EDIT shares in the open market
3. Sep 3, 2025 · this disclosureInsiderCEO sold ~$15K of EDIT shares in the open market

What came next

1. Sep 3, 2025Insider · 2 peopleInsiders: 2 sales (~$3K)
2. Nov 10, 2025Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Editas Medicine

For Editas Medicine, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EDIT page.

Other recent filings by Gilmore Neil O'neill, CEO

• SEC Form 4 at Editas Medicine (EDIT)Jun 4, 2025
• SEC Form 4 at Editas Medicine (EDIT)Mar 5, 2025
• SEC Form 4 at Editas Medicine (EDIT)Dec 5, 2024

The full history of Gilmore Neil O'neill, CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Editas Medicine

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Sep 4, 2025
• SEC Form 4Sep 4, 2025
• SEC Form 4Aug 8, 2025
• SEC Form 4Aug 4, 2025

Everything OQRO holds on this company is on its EDIT page.